EcoActive / Intralytix - LARVOL DELTA

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease (clinicaltrials.gov) - P1/2 | N=30 | Active, not recruiting | Sponsor: Intralytix, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2024 ➔ Jun 2026 | Trial primary completion date: Sep 2024 ➔ Jun 2026

Enrollment closed • Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

Comparison of Crohn's disease-associated adherent-invasive Escherichia coli (AIEC) from France and Hong Kong: results from the Pacific study. (PubMed, Gut Microbes) - "When tested for antibiotic resistance, the proportion of AIEC strains resistant to ampicillin, piperacillin, tobramycin, and gentamicin was significantly higher in HK AIEC strains compared to French strains. Moreover, genomic analysis of 25 FR and 17 hK AIEC strains using next-generation sequencing revealed the co-existence of several virulence factors associated with enteric E. coli pathotypes, although no single virulence factor was significantly associated with either country of origin or AIEC status. In vitro, all AIEC strains (FR and HK) were sensitive to the EcoActive™ phage cocktail, suggesting that it could be a promising option to target AIEC in CD across the world."

Clinical • Journal • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Intralytix, Inc. | Trial completion date: Sep 2023 ➔ Sep 2024 | Trial primary completion date: Sep 2023 ➔ Sep 2024

Trial completion date • Trial primary completion date • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP

COMPARISON OF CROHN'S DISEASE-ASSOCIATED ADHERENT-INVASIVE ESCHERICHIA COLI (AIEC) FROM FRANCE AND HONG-KONG: RESULTS FROM THE PACIFIC STUDY (DDW 2023) - "The proportion of AIEC strains resistant to antibiotics was higher in HK AIEC strains compared to French strains regarding ampicillin (2.9-fold) piperacillin (3-fold), tobramycin (25-fold) and gentamycin (25-fold higher). The prevalence, phenotype, and genetic composition of AIEC bacteria are similar in FR and HK except for the antibiotic resistance profile reinforcing its ubiquitous role in CD. The EcoActive TM phage cocktail, showing a strong lytic potency against AIEC strains from both FR and HK, may offer a safe and effective therapeutic option to target AIEC regardless of their geographical origin."

Crohn's disease • Gastroenterology • Immunology • Inflammation • Inflammatory Bowel Disease

Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease (clinicaltrials.gov) - P1/2 | N=30 | Recruiting | Sponsor: Intralytix, Inc. | Trial primary completion date: Aug 2022 ➔ Sep 2023

Trial primary completion date • Crohn's disease • Gastroenterology • Genetic Disorders • Immunology • Inflammatory Bowel Disease • CRP